AbbVie Inc. beat EPS estimates 94% of the time across 18 reported quarters (17 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $3.78 | — | — | Miss |
| Q1 FY2026 | $2.59 | $2.65 | +2.3% | Beat |
| Q1 FY2026 | $3.03 | — | — | Miss |
| 2026-02-04 | $2.65 | $2.71 | +2.3% | Beat |
| Q3 FY2025 | $1.77 | $1.86 | +5.1% | Beat |
| Q2 FY2025 | $2.88 | $2.97 | +3.1% | Beat |
| Q1 FY2025 | $2.38 | $2.46 | +3.4% | Beat |
| 2025-01-31 | $2.98 | $2.16 | -27.5% | Miss |
| Q3 FY2024 | $2.92 | $3.00 | +2.7% | Beat |
| Q2 FY2024 | $2.57 | $2.65 | +3.1% | Beat |
| Q1 FY2024 | $2.26 | $2.31 | +2.2% | Beat |
| 2024-02-02 | $2.76 | $2.79 | +1.1% | Beat |
Back to ABBV overview · ABBV holders · ABBV KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.